Synthesis and Cytotoxicity Evaluation of N-(5-(Substituted-benzylthio)-1,3,4-thiadiazole-2-yl)-2-p-nitrophenylacetamide Derivatives as Potential Anticancer Agents

Document Type : Research Article


1 Pharmaceutical Sciences Research Center, Health Institute, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, I.R. IRAN

2 Department of Medicinal Chemistry, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, I.R. IRAN

3 Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, I.R. IRAN

4 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, I.R. IRAN


Cancer is a big global problem and is one of the top and main causes of mortality in developed countries. Many of the current treatments and anticancer therapeutics have problems with severe side effects and on the other hand, the drug resistance is also another obstacle in the cancer chemotherapy. Hence, there is a strong demand for the discovery and development of effective new antineoplastic therapies. According to the in vitro effectiveness of 1,3,4-thiadiazole based compounds as anticancer agents, new 1,3,4-thiadiazole based derivatives with various electron withdrawing and electron donating moieties were synthesized and tested by MTT assay against three cancerous cell lines. PC3 (Prostate cancer), U87-C-531 (Glioblastoma) and MDA-MB-231 (Breast cancer) cell lines were applied for MTT assay and obtained results were compared to imatinib. Study of the structure activity relationship of prepared compounds showed electron withdrawing substituents such as Cl, F and NO2 enhanced the anticancer properties compared to compound without any substituent (compound 3l) or compounds with electron donating (methoxy) substituent (compounds 3j and 3k). Totally, compound 3a (IC50 = 10.6 µM) showed superior activity against PC3 cell line and compounds 3d  (IC50 = 10.3 µM), 3h (IC50 = 12.5 µM) and 3j (IC50 = 11.3 µM) exhibited higher activity against MDA-MB-231 cell line compared to imatinib as reference drug.


Main Subjects

[1] Levitzki A., Klein S., Signal Transduction Therapy of Cancer, Mol Aspects Med., 31(4): 287-329 (2010).
[3] Rafael Sierra J., Cepero V., Giordano S., Molecular Mechanisms of Acquired Resistance to Tyrosine Kinase Targeted Therapy, Mol. Cancer, 9: 75-87 (2010).
[4] Arora A., Scholar E.M., Role of Tyrosine Kinase Inhibitors in Cancer Therapy, J. Pharmacol. Exp. Ther., 315(3): 971-979 (2005).
[5] Kumar D., Reddy Vaddula B., Kuei-Hua Chang K.H., Shah K., One-Pot Synthesis and Anticancer Studies of 2-arylamino-5-aryl-1,3,4-thiadiazoles, Bioorg. Med. Chem. Lett., 21(8):2320-2323 (2011).
[6] Farshori N.N., Banday R.M., Ahmad A., Khan A.U, Rauf A., Synthesis, Characterization, and in Vitro Antimicrobial Activities of 5-alkenyl/ hydroxyalkenyl- 2-phenylamine-1,3,4-oxadiazoles and Thiadiazoles, Bioorg. Med. Chem. Lett., 20(6): 1933-1938 (2010).
[7] Reddy C.S., Rao L.S., Nagaraj A., Synthesis and Evaluation of Novel Bis[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles as Potent Antimicrobial Agents, Acta Chim. Slov.,57(3):7 26-732 (2010).
[8] Purohit D.H., Dodiya B.L., Ghetiya R.M., Vekariya P.B., Joshi H.S., Synthesis and Antimicrobial Activity
of some New 1,3,4-Thiadiazoles and 1,3,4-Thiadiazines Containing 1,2,4-Triazolo Nucleus
, Acta Chim. Slov.,58(1): 53-59 (2011).
[9] Li Y., Geng, J., Liu, Y., Yu, S., Zhao, G., Thiadiazole-a Promising Structure in Medicinal Chemistry, Chem. Med. Chem., 8(1):27-41 (2013).
[10] Singh A.K., Mishra A., Jyoti K., Review onBiological Activities of 1,3,4-Thiadiazole Derivatives, J. Applied Pharm. Sci., 1(5):44-49 (2011).
[11] Haider S., Alam M.S., Hamid H., 1,3,4-Thiadiazoles: A Potent Multi Targeted Pharmacological Scaffold, Eur. J. Med. Chem., 92: 156-177 (2015).
[12] Matysiak J., Opolski A., Synthesis and Antiproliferative Activity of N-substituted 2-amino-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles, Bioorg. Med. Chem., 14(13): 4483-4489 (2006).
[13] Mohammadi-Farani A., Heidarian N., AliabadiA., N-(5-Mercapto-1,3,4-thiadiazol-2-yl)-2-phenylacetamide Derivatives: Synthesis and in Vitro Cytotoxcity Evaluation as Potential Anticancer Agents, Iran. J. Pharm. Res., 12(2): 487-492 (2014).
[14] Rzeski W., Matysiakb J., Kandefer-Szerszen M., Anticancer, Neuroprotective Activities and Computational Studies of 2-amino-1,3,4-thiadiazole Based Compound., Bioorg. Med. Chem., 15(9): 3201-3207 (2007).
[15] Chou J.Y., Lai S.Y., Pan S.L., Jow G.M., Chern J.W., Guh J.H., Investigation of Anticancer Mechanism of Thiadiazole-Based Compound in Human Non-Small Cell Lung Cancer A549 Cells, Biochem. Pharmacol. 66(1): 115-124 (2003).
[16] Yang X.H., Wen Q., Zhao T.T., Sun J., Li X., Xing M., Lu X., Zhu H.L., Synthesis, Biological Evaluation, and Molecular Docking Studies of Cinnamic Acyl 1,3,4-thiadiazole Amide Derivatives as Novel Antitubulin Agents, Bioorg. Med. Chem., 20(3): 1181-1187 (2012).
[17] Sun J., Yang Y.S., Li W., Zhang Y.B., Wang X.L., Tang J.F., Zhu H.L., Synthesis, Biological Evaluation and Molecular Docking Studies of 1,3,4-Thiadiazole Derivatives Containing 1,4-Benzodioxan as Potential Antitumor Agents, Bioorg .Med. Chem. Lett., 21(20): 6116-6121 (2011).
[19] Aliabadi A., Mohammadi-Farani A., Hosseinzadeh Z, Nadri H., Moradi A., Ahmadi F. Phthalimide Analogs as Probable 15-lipoxygenase-1 Inhibitors: Synthesis, Biological Evaluation and Docking Studies, Daru: J. Pharm. Sci., 23: 36-43 (2015).
[21] Radi M., Crespan E., Botta G., Falchi F., Maga G., Manetti F., Corradi V., Mancini M., Santucci M.A., Schenone S., Botta M., Discovery and SAR of 1,3,4-thiadiazole Derivatives as Potent Abl Tyrosine Kinase Inhibitors and Cytodifferentiating Agents, Bioorg. Med. Chem. Lett., 18(3): 1207-1211 (2008).
[22] Crespan E., Radi M., Zanoli S., Schenone S., Botta M., Maga G., Dual Src and Abl Inhibitors Target Wild Type Abl and the AblT315I Imatinib-Resistant Mutant with Different Mechanisms, Bioorg. Med. Chem., 18(11): 3999-4008 (2010).
[23] Aliabadi A., Shamsa F., Ostad S.N., Emami S., Shafiee A., Davoodi J., Foroumadi A., Synthesis and Biological Evaluation of 2-phenylthiazole-4-Carboxamide Derivatives as Anticancer Agents, Eur. J. Med. Chem., 45(11): 5384-5389 (2010).